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ABSTR ACT
OBJECTIVE: To compare the effects of different protocols of controlled ovarian hyperstimulation on thyroid function with those of the natural menstrual cycle. 
STUDY DESIGN: Prospective controlled study. 
SETTING: University Medical Center. 
PATIENTS: A total of 97 women without a history of endocrine disease undergoing intrauterine insemination either in a natural cycle, or with mild ovarian 
hyperstimulation, or in vitro fertilization (IVF). 
MAIN OUTCOME MEASURES: estradiol (E2), thyroxine binding globulin (TBG), free thyroxine (FT4), total thyroxine (TT4) and thyroid stimulating 
hormone (TSH) during the midluteal phase. 
RESULTS: In the IVF group midluteal E2, TBG, and TT4 were significantly higher; midluteal FT4 was significantly lower (mean difference: -1.46 pmol/L; 
P  0.001) and midluteal TSH was significantly higher (mean difference: 0.52 mU/L; P = 0.015). 
CONCLUSIONS: Ovarian hyperstimulation in IVF is associated with lower midluteal FT4 and higher midluteal TSH levels compared to the natural cycle.
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Introduction
In healthy pregnant women, the thyroid gland maintains 
euthyroidism, with only minor fluctuations in serum free thy-
roxine (FT4) and thyroid stimulating hormone (TSH).1,2 A 
high circulating chorionic gonadotropin level in the first tri-
mester leads to interactions with the TSH receptors, prompt-
ing a temporary increase in FT4 and the partial suppression of 
TSH.1,2 Also, estradiol (E2) promotes increased serum levels 
of T4-binding globulin (TBG), accompanied by a decrease in 
serum FT4, which is followed by a rise in TSH and total thyrox-
ine (TT4), resulting in a new equilibrium.1,2 In women under-
going assisted reproductive technology (ART)  procedures, 
however, controlled ovarian hyperstimulation (OH) leads to 
E2 levels that are usually higher than in the first trimester of 
pregnancy.2 In women with subclinical or overt hypothyroid-
ism, or in euthyroid women with thyroid autoimmunity (TAI), 
there is an increased frequency of adverse pregnancy outcomes 
(ie, a higher risk of miscarriage, preterm delivery, and impaired 
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psychomotor development in the offspring).3–10 Whether alter-
ations of thyroid function during OH could influence ART 
and pregnancy outcomes is unclear. Several studies have evalu-
ated thyroid parameters during OH,11–14 or in the first month 
of pregnancy after OH.15–17 However, the evidence concerning 
the effect of OH on  thyroid function is contradictory,18 prob-
ably due to the fact that alterations in thyroid function during 
OH are dependent on the duration and the amount of incre-
ment in E2 levels. Our aim was to investigate the changes in 
thyroid function during OH. Therefore, we conducted a study 
to determine the effect of different regimes of OH on thyroid 
function during ART, and to compare these effects with the 
natural menstrual cycle.
Materials and Methods
Overall study design. We studied 97 women from infer-
tile couples who presented at our center. The participants were 
prospectively included between January 2000 and February 
2003 after their written informed consent was provided. 
The study was approved by the Institutional Review Board 
of the Erasmus University Medical Centre (Rotterdam, the 
Netherlands). We included 20 women who underwent intra-
uterine insemination (IUI) without ovarian stimulation in a 
natural cycle (IUI-NC), 27 women who underwent IUI with 
mild OH (IUI+MOH), and 50 women undergoing in vitro 
fertilization (IVF) who were participating in a randomized 
study19 with three different stimulation protocols for assisted 
reproduction. The inclusion criteria for IUI-NC were: 1) age 
between 18 and 38 years; 2) cervical hostility; or 3) male factor 
infertility, according to Tygerberg’s strict criteria.20 The inclu-
sion criterion for IUI+MOH was unexplained subfertility. 
The inclusion criteria in women undergoing IVF were: 1) age 
between 20 and 38 years; 2) body mass index between 19 kg/m2 
and 29 kg/m2; 3) history of regular menstrual cycles ranging 
from 25–35 days; 4) no relevant systemic disease, severe endo-
metriosis, or uterine or ovarian abnormalities; 5) no more than 
three previous IVF cycles; and 6) no previous IVF cycle with 
a poor response or OH syndrome.19 The exclusion criterion for 
all participants in this study was history of a previous endo-
crine disease, as assessed from the patients’ medical history. 
Women with known thyroid disease and/or on any thyroid 
medication were also excluded from the study.
E2, TBG, FT4, TT4, and TSH were determined at cycle 
days 2–5 (baseline), at the day of (or the day before) human 
chorionic gonadotropin (hCG) injection, at the day of IUI/
ovum pick-up (OPU) and 6–7 days after insemination/OPU 
(midluteal).
ART treatment. In IUI-NC, follicular growth was mon-
itored by transvaginal ultrasound. In IUI+MOH, a daily dose 
of 75–150 IU of human menopausal gonadotropin (Metrodin 
HP®; Merck KGaA, Darmstadt, Germany) was adminis-
tered subcutaneously (sc), starting on day 5 of the cycle, until 
a transvaginal scan showed at least one follicle with a diam-
eter of 17–18 mm. The aim of MOH was to obtain two or 
three dominant follicles with a diameter of at least 18 mm. 
In both IUI-NC and IUI-MOH, a sc dose of 5.000 IU hCG 
(Profasi®, Merck KGaA) was administered when the leading 
follicle had reached an average diameter of 17–18 mm. IUI 
was performed approximately 36–40 hours later.
After assignment to IVF, patients were randomized to 
one of the three treatment protocols: 1) treatment with the 
gonadotropin-releasing hormone (GnRH) agonist, trip-
toreline (Decapeptyl®; Ferring B.V. Group, Hoofddorp, 
the Netherlands), 1 mg sc daily, starting 1 week before the 
expected menses; 2) treatment with recombinant follicle 
stimulating hormone (recFSH) 150 IU sc daily (GONAL-f®; 
Merck KGaA), beginning once downregulation was achieved; 
or 3) treatment with the same dose of recFSH, starting on 
cycle day 2 or 5, in combination with the GnRH antagonist, 
cetrorelix (Cetrotide®; Merck KGaA), at a dose of 0.25 mg sc 
daily, beginning when the largest follicle reached a diameter 
of 14 mm.19 The aim of OH in IVF was to obtain three or 
more dominant follicles. Administration of both the GnRH 
agonist/antagonist was continued up to and including the 
day of hCG administration. When the patient had at least 
three follicles with a diameter 15 mm and the leading fol-
licle had reached a diameter of 18 mm, administration of 
recFSH was discontinued, and ovulation was induced with 
10.000 IU hCG sc (Pregnyl®; Schering-Plough Corpora-
tion, Kenilworth, NJ, USA). Approximately 35 hours after 
the hCG injection, transvaginal ultrasound-guided oocyte 
retrieval was performed. Subsequently, IVF with or without 
intracytoplasmic sperm injection was performed. Luteal sup-
port was given using the vaginal administration of 200 mg 
of progesterone (Progestan®; Schering-Plough Corporation) 
three times daily, starting on the day of oocyte retrieval until 
the pregnancy test.
Hormone assays. Serum from collected blood samples 
was coded and stored at -20°C until analysis. All samples 
were analyzed in a random order in one series. TSH levels 
were determined with the Immulite® 2000 analyzer (Sie-
mens AG, Munich, Germany) and FT4 with the Vitros® ECi 
analyzer (Ortho Clinical Diagnostics, Johnson & Johnson 
Medical BV, Tilburg, the Netherlands). Reference ranges 
were: TSH, 0.4–4.0 mU/L; and FT4, 11–25 pmol/L. TT4 was 
determined with an in-house radioimmunoassay (RIA) with a 
reference range of 64–132 nmol/L. TBG was determined by 
RIA (Brahms, Berlin, Germany). E2 was determined by RIA 
(Siemens-DPC, Los Angeles, CA, USA). Inter- and intraas-
say coefficients of variation were, respectively: TSH 4.1% 
and 3.4%; FT4 5.4% and 2.7%; TT4 4.6% and 2.8%; 
E2 10.2% and 8.8%; and TBG 3.8% and 3.3%.
Statistical analysis. Statistical analysis was limited to 
subjects for whom both a baseline sample and at least one 
other sample during the study period were available. In total, 
25 of 388 samples were missing (five at time point 2, two 
samples in IUI-NC and three samples in IUI-MOH; five at 
time point 3, two samples in IUI-NC and three samples in 
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IUI-MOH; and 15 at time point 4, four samples in IUI-NC 
and eleven samples in IUI-MOH). Among 78 of 97 women, 
sampling was complete at all time points. We excluded four 
women from the statistical analysis because there was no blood 
sample available from time point 1. The subjects  undergoing 
IVF in the three different stimulation protocols were analyzed 
together in one group (IVF). Comparisons of the baseline 
data between the three groups were performed using the chi-
square test for qualitative data and the Kruskal–Wallis test 
for continuous data. Results are presented as the median and 
range, unless otherwise indicated. A linear mixed model was 
used 1) to compare hormone levels at various time points dur-
ing OH compared to baseline; and 2) to calculate the mean 
differences and 95% confidence intervals (CI) between base-
line and the midluteal hormone levels, and to compare the dif-
ferences between the three treatment groups. Correlations are 
expressed as Pearson’s correlation coefficient. All data analy-
ses were performed using SPSS version 18.0 (IBM Corpora-
tion, Armonk, NY, USA). Statistical significance was set at 
the P  0.05 level.
Results
Baseline characteristics. The clinical and endocrine 
baseline characteristics of women enrolled in this study are 
shown in Table 1. The participants did not differ significantly 
with respect to their family history of thyroid disease, age, 
body mass index, and E2, TBG, FT4, and TT4 levels at base-
line. The three treatment groups differed significantly in terms 
of cause of infertility (P = 0.004) and TSH levels (P = 0.001). 
Of all patients, eight in the IVF group and none in the IUI 
groups underwent a fertility treatment in the previous cycle. 
After exclusion of these previously treated patients from the 
statistical analysis, similar results were obtained.
Differences in thyroid function between the time 
points by treatment group. Table 2 shows the mean values 
and 95% CI of the hormone levels by time point. Serum E2 
peaked in all groups on the day of hCG administration (visit 2); 
serum TBG peaked in the IUI+MOH and IVF group at 
the midluteal phase (visit 4); FT4 significantly decreased in 
the IVF group at ovum pick-up (visit 3) and at the midluteal 
phase (visit 4); and TT4 and TSH peaked in the IVF group at 
the midluteal phase (visit 4). Compared to baseline, TSH lev-
els in the IUI-NC group were significantly lower upon hCG 
administration (visit 2) and at the midluteal phase (visit 4), 
whereas the TSH levels in the IVF group were significantly 
higher at the midluteal phase (visit 4). 
Differences in thyroid function between the treatment 
groups. Figure 1 shows the mean hormone levels with stan-
dard error (SE) bars of the three treatment groups by time 
point, and Table 3 summarizes the differences of the midlu-
teal hormone levels as they change from baseline. 
Correlations. There was a significant correlation between 
midluteal TBG and E2 (r = 0.61; P  0.001; Fig. 2), between 
midluteal FT4 and TBG (r = -0.3; P  0.005; Fig. 3), and 
between midluteal E2 and FT4 (r = -0.28; P = 0.01; Fig. 4). 
Finally, there was no significant correlation between midlu-
teal FT4 and TSH (r = 0.08; P = 0.47; data not shown).
Discussion
In this prospective controlled study, we investigated the 
effects of different regimes of OH on thyroid function. We 
found higher midluteal E2, TBG, and TT4 serum levels and 
Table 1. patient characteristics.
IUI-NC
(n = 20)
IUI+MOH
(n = 27)
IVF 
(n = 50)
P-VALUE
no. of patients with a family history  
of thyroid disease (%)
0 3 (11) 0 .09
Cause of infertility (%)
unexplained 0 27 (100) 15 (30)
.004
Male factor 20 (100) 0 19 (38)
tubal factor 0 0 7 (14)
combination (male and female factor) 0 0 4 (8)
other (endometriosis/ovulation disorder) 0 0 5 (10)
patient age (yr)ª 31 (21–41) 32 (22–39) 33 (25–38) .16
BMi (kg/m²)ª 24 (19–33) 23 (20–39) 23 (20–29) .74
Baseline e2 (pmol/l)ª 188 (10–824) 158 (43–469) 137 (7–389) .11
Baseline tBg (mg/l)ª 20 (11–26) 20 (15–24) 20 (9–30) .11
Baseline Ft4 (pmol/l)ª 16 (14–22) 16/13–24 14 (12–20) .07
Baseline tt4 (nmol/l)ª 92 (76–127) 94 (73–118) 91 (7–129) .08
Baseline tsh (mu/l)ª 1.7 (0.8–4) 1.7 (0.1–4.4) 0.8 (0.1–4.4) .001
Note: ªvalues are medians (range).
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Table 2. serum hormone levels by time points.
ART TREATMENT VISIT E2 (pmol/L) TBG (mg/L) FT4 (pmol/L) TT4 (nmol/L) TSH (mU/L)
iui-nc
n = 20
1 185 (146–236) 19.6 (18.8–20.4) 16.6 (16.0–17.2) 95.6 (92.6–98.6) 1.92 (1.69–2.15)
2 546 (424–704)** 18.5 (17.7–19.4) 16.4 (15.7–17.0) 92.4 (89.3–95.5) 1.54 (1.29–1.78)*
3 352 (274–454)** 18.9 (18.1–19.8) 16.8 (16.2–17.5) 93.8 (90.7–96.9) 1.85 (1.60–2.09)
4 428 (328–561)** 19.0 (18.1–20.0) 16.6 (15.9–17.3) 91.6 (88.3–95.0) 1.52 (1.26–1.78)*
iui+Moh
n = 27
1 164 (138–196) 19.3 (18.6–20.1) 16.4 (15.9–17.0) 94.1 (91.7–96.5) 1.72 (1.49–1.95)
2 957 (794–1154)** 18.6 (17.8–19.4) 16.0 (15.4–16.5) 90.8 (88.3–93.4) 1.61 (1.37–1.86)
3 616 (512–743)** 19.3 (18.5–20.1) 16.1 (15.6–16.7) 93.1 (90.5–95.7) 1.83 (1.59–2.08)
4 556 (442–698)** 20.6 (19.6–21.6)* 15.8 (15.1–16.5) 93.2 (90.1–96.4) 1.73 (1.43–2.03)
ivF
n = 50
1 127 (106–152) 19.7 (18.7–20.6) 14.8 (14.5–15.1) 93.8 (90.4–97.2) .95 (0.81–1.09)
2 2695 (2252–3224)** 19.1 (18.1–20.1) 14.4 (14.1–14.7) 90.1 (86.7–93.6) .95 (0.82–1.09)
3 1387 (1159–1659)** 20.7 (19.7–21.7) 14.2 (13.9–14.5)* 95.9 (92.5–99.3) 1.12 (0.98–1.26)
4 1676 (1400–2005)** 24.1 (23.1–25.1)** 14.2 (13.9–14.5)** 106.4 (103–110)** 1.25 (1.11–1.39)**
Notes: visit: 1=baseline; 2=hcg-administration; 3=intra uterine insemination/ovum pick-up; 4=midluteal. 
Data are presented as means with 95% confidence intervals. 
Tests of significance reflect pair wise comparisons with results obtained at visit 1. 
*P  .05; **P  .001.
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lower FT4 serum levels after OH compared to the natural 
cycle. Furthermore, we found higher midluteal TSH serum 
levels in IVF women compared to those with a natural cycle. 
Women undergoing OH for IVF showed the highest E2 lev-
els from the moment of hCG administration, and the lowest 
FT4  levels during the midluteal phase. These lower FT4 serum 
levels are likely to be a result of the administered FSH, result-
ing in elevated E2 and consequently leading to increased TBG 
serum levels. Our study confirms the association between 
elevated E2 and TBG serum levels, and the reduction in FT4 
levels during OH.11 Our results also indicate that OH during 
IVF may induce suboptimal thyroid hormone levels around 
the time of implantation. We think that the regulation of thy-
roid hormone levels during OH and in early pregnancy after 
IVF needs further study, since any condition resulting in a rise 
of TSH or a decreased FT4 could potentially be harmful for 
pregnancy outcomes.
None of the participants suffered from clinical or sub-
clinical hypothyroidism and, during the study, TSH and FT4 
levels were within the normal range. However, at baseline, 
women undergoing IVF had markedly lower FT4 and TSH 
values than did women undergoing IUI-NC or IUI+MOH. 
Therefore, one could speculate that women undergoing IVF, 
with a longer history of infertility were principally different 
from those in the two other groups. An explanation could 
be that their pituitary–thyroid axis might work at a lower set 
point, contributing to their infertility. 
Several studies have reported on thyroid function during 
OH in IVF patients.11–14 Muller et al11 reported in a study of 
65 women a significant decrease in FT4 and an increase in 
E2, TBG, and TSH at stimulation at day 14 when compared 
to baseline. In a prospective cohort study of 57 euthyroid or 
hypothyroid-treated women, Gracia et  al12 showed a rapid 
increase in E2 (which peaks upon hCG administration), an 
increase in TSH that peaks 1 week later and, simultaneously, 
a significant increase in FT4 and TT4. The authors also rec-
ognized elevated TBG levels that remained high during the 
first trimester.12 Monteleone et al13 observed in 31 euthyroid 
women no significant changes in FT4 and TSH levels during 
OH, or at the day of the pregnancy test as compared to base-
line. Kim et al14 randomized 64 women with subclinical hypo-
thyroidism to levothyroxine treatment or no treatment during 
IVF. Although the authors described differences in thyroid 
parameters between the treatment and control groups during 
OH, they did not report the changes of TSH and FT4 when 
compared to baseline.14 Poppe et  al15–17 examined, in three 
studies, thyroid function in the first month of pregnancy after 
IVF, and they found an increase of FT4 and TSH levels com-
pared to prestimulation levels. The results in a number of these 
studies are concordant with ours and some are not. However, 
all studies were limited to patients during or after OH in IVF 
without the inclusion of an unexposed control group.
Maternal thyroid hormone levels in the first trimes-
ter of pregnancy are related to the developmental indices of 
the child. Pop et  al6 reported that the developmental index 
of a child is related to the mother’s first trimester FT4 level, 
irrespective of whether or not TSH and thyroid peroxidase 
antibodies (TPO-Ab) were elevated. Women with a first- 
trimester FT4 value equal to or below the tenth percentile had 
a relative risk of 5.8 for a child with a developmental index, 
which was more than one standard deviation below the mean 
at 10 months of age. None of these women were suffering 
from clinical or subclinical hypothyroidism.6 Another study 
by the same group7 consisted of a 2-year follow-up of chil-
dren born to mothers who had hypothyroxinemia without a 
recorded status of TPO-Ab at 12 weeks of gestation. Here, 
too, a significantly delayed mental and motor development of 
the offspring was found at 1 year (a 10-point lower intelligence 
score and an 8-point lower motor score than normal controls) 
and 2 years of age (an 8-point lower intelligence score and a 
10-point lower motor score than normal controls).7 Li et al21 
investigated thyroid function in women at 16–20 weeks of 
gestation retrospectively, and evaluated the intelligence and 
motor score of their children at 25–30 months of age in order 
to examine the individual effects of subclinical hypothy-
roidism, hypothyroxinemia, and elevated TPO-Ab titers on 
neuropsychological development. Children of women with 
subclinical hypothyroidism, hypothyroxinemia, and elevated 
TPO-Ab titers had mean intelligence scores 8.88, 9.30, and 
10.56 points lower than those of the controls and mean motor 
scores were 9.98, 7.57, and 9.03 points lower than those of the 
controls.21 Finally, a large population-based cohort study22 
on maternal hypothyroxinemia at 13 weeks’ gestation, as well 
as children’s verbal and nonverbal cognitive development at 
18 months and 30 months, which included 3,659 children and 
their mothers, reported that mild and severe maternal hypo-
thyroxinemia was associated with a significantly higher risk 
of expressive language delay across all ages. Severe maternal 
hypothyroxinemia also predicted a significantly higher risk of 
nonverbal cognitive delay.22 
Within an individual, thyroid hormone concentrations 
are maintained within relatively narrow limits. Therefore, 
test results that fall considerably outside the normal range for 
the individual being tested may appear normal when using 
conventional population-based reference intervals, and a test 
result within the laboratory’s reference limits, is not necessarily 
normal for that individual.23 This emphasizes that FT4 serum 
levels in the lower reference range, as found in our study before 
and after OH, could be of importance for individual women 
during a subsequent pregnancy. The mother herself may syn-
thesize and secrete just enough T4 and T3 to meet her own 
needs, but the amount of FT4 reaching the embryo or the fetus 
might not be sufficient for its normal neurodevelopment.6,7
The physical, neurological, and developmental health 
of children born after ART has been examined in many epi-
demiological studies, with contradictory results. Most small 
studies reported no effect,24–31 whereas the larger studies have 
found an increased risk of developmental delay.32–35 A recent 
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systematic review and meta-analysis has also addressed the 
question of developmental delay in children born after ART. 
The authors conclude that the risk of serious developmen-
tal delay following ART appears to be small, but that larger 
studies conducted on samples of low- and high-risk children 
conceived by ART are needed.36 In another recent systematic 
review,37 it was concluded that many existing studies of the 
neurodevelopmental effects of ART were difficult to inter-
pret due to methodological shortcomings. Furthermore, the 
included studies did not allow for a conclusion to be drawn 
about the risk of minor neurodevelopmental disorders, because 
their detection requires more specific tests at ages above 
2 years.37
The limitations of our study are that we did not monitor 
the TAI state and the thyroid function during the first tri-
mester in our population. Therefore, one could argue that the 
observations from our study only represent a transient phe-
nomenon with only marginal or no clinical significance. On 
the other hand, if women who are receiving OH treatment 
tend to have lower serum FT4, already during the first days of 
pregnancy, increased levels of E2 could further contribute to 
a disturbance of their thyroid function, and a clinically sig-
nificant effect might be observed, for example, in women with 
preexisting hypothyroxinemia or with TAI.
Conclusion
The mechanisms that intervene with thyroid function during 
and after OH are complex, but our results indicate that the 
effect of OH during ART on thyroid function is dependent 
on the increment of E2 levels. Larger prospective studies are 
needed to further elucidate the relation between OH and thy-
roid function in subfertile, euthyroid women with or without 
TAI, untreated subclinical hypothyroidsm, and treated hypo-
thyroidism. These studies should investigate thyroid param-
eters during OH and during the subsequent pregnancy, and 
they should also explore the development of the children.
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